Transition metal ion-catalyzed oxygen activation during pathogenic processes  by Hippeli, Susanne & Elstner, Erich F
Minireview
Transition metal ion-catalyzed oxygen activation during pathogenic
processes
Susanne Hippeli, Erich F. Elstner*
Lehrstuhl fuºr Phytopathologie, Labor fuºr Angewandte Biochemie, Technische Universitaºt Muºnchen, Am Hochanger 2,
85350 Freising-Weihenstephan, Germany
Received 19 October 1998; received in revised form 30 November 1998
Abstract Most pathological processes include the production of
activated oxygen species augmented or attenuated by transition
metal ions catalyzing one electron transitions. Inhalation of
airborne particles, infections, ingestion of toxins or liberation
from endogenous stores represent biological pathways for the
induction of pathogenic processes by these metal ions. In this
short review basic reactions involving transition metal ions
operating during oxidative stress in certain diseases will be
discussed.
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1. Introduction
Atmospheric oxygen has to be activated in order to react
with organic molecules. This is due to the fact that molecular
oxygen is an unreactive molecule in the triplet ground state
(3O2) and has to be activated in order to react with atoms or
molecules in the (‘normal’) singlet ground state thus circum-
venting spin-forbidden reactions. These processes of activa-
tion include very reactive intermediates. Therefore, aerobic
cells must cope with, and to some extent also adapt to, oxi-
dative stress provoked for example by infections or intoxica-
tions, where reactive intermediates of oxygen accumulate.
Most visible or measurable disease symptoms are connected
with oxygen activation where principally a transition from
heterolytic (two electron transitions) to increased homolytic
(one electron transitions) reactions is observed. Homolytic
reactions produce free radicals, which are generally counter-
acted by a parallel increase of intrinsic radical scavenging
processes or by compounds administered with food thus war-
ranting metabolic control within certain limits. Most transi-
tion metals belonging to the fourth period due to their elec-
tron motility in the third shell which is ¢lled up in the series
from scandium (8 electrons) to zinc (18 electrons) can easily
undergo one electron redox reactions. These may include elec-
tron donations to oxygen forming superoxide or to hydrogen
peroxide, forming the extremely reactive OH radical thus in-
ducing or strongly increasing oxygen stress in cells, tissues,
organs and ¢nally organisms visible or measurable as disease
symptoms.
In a recent review Saran et al. [1] stated that: ‘‘there is
probably not a single radical chain process in vivo that pro-
ceeds without the participation of some metal in loose or
bound form, whether as a side e¡ect or even playing a dom-
inant role’’ thus emphasizing a biochemical dogma based on a
wealth of publications of the last 20 years.
2. Oxygen activation and reactive oxygen species (ROS)
De¢ciencies in transition metal ions (TMI) can cause severe
disease symptoms, with iron de¢ciency causing anemia as the
best known example. Overload by TMI, on the other hand,
due to intoxication or an inherited disease also results in
pathological symptoms often ameliorated by sequestration
of the corresponding TMI by chelators. Many of the well-
known diseases ^ independent of an overload or genetic de¢-
ciency ^ such as diabetes, arthritis, ischemia-reperfusion dam-
age, cancer, arteriosclerosis, sunburn and many others in-
clude, or are governed by, both ROS and TMI. The
interaction of ROS and TMI is complex and based on several
initial and secondary processes [2]. The most important reac-
tions concerning this subject will be brie£y addressed; the
whole ¢eld of oxygen biochemistry has been frequently re-
viewed and several books on this topic have appeared [3^5].
This short review will not go too deeply into details of the
chemistry of oxygen-TMI interactions, since this ¢eld has
been covered exhaustively by Martell and Sawyer [2].
2.1. Homolytic and heterolytic reactions: how are free radicals
created?
During heterolytic reactions electron pairs are transferred,
either utilizing or creating ions. Homolytic reactions create
radicals through the transfer of single electrons, represented
as a dot. A radical is a compound containing an unpaired
electron. There are stable and unstable radicals. Most free
radicals are highly reactive creating new radicals thus initiat-
ing chain reactions. This holds especially for lipids in mem-
branes.
3. Mechanisms of oxygen activation
3.1. Photodynamic reactions
Oxygen activation may occur via photodynamic reactions
through activated pigment states (P*), where exciton transfer
from the pigment (mostly aromatic or heterocyclic com-
pounds) may form singlet oxygen (type II reaction). Singlet
FEBS 21400 18-1-99
0014-5793/99/$19.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 1 6 6 5 - 2
*Corresponding author. Fax: (49) (8161) 714538.
E-mail: Elstner@lrz.tum.de
Abbreviations: DF, desferrioxamine, Desferal; EDTA, ethylene dia-
mine tetraacetate; Hb, hemoglobin; IRP, iron regulatory protein;
PMNL, polymorphonuclear leukocytes ; RC, redox-cycling com-
pound; ROS, reactive oxygen species; SOD, superoxide dismutase;
TC, tungsten carbide; TMI, transition metal ions
FEBS 21400 FEBS Letters 443 (1999) 1^7
oxygen in contrast to atmospheric oxygen is not subject to the
spin rule and reacts rapidly with most organic molecules
(RH), especially at double bonds of unsaturated fatty acids,
producing hydroperoxides which can be activated by Fe2
reductively released from endogenous stores [6].
Photodynamic reactions not involving physical transfer of
excitation energy via P* and 1O2 but undergoing charge sep-
aration within the excited pigment are called photodynamic
reactions type I.
3.2. Reductive oxygen activation: formation of primary oxygen
radicals
In the presence of reductants of su⁄cient a⁄nity for oxygen
and an appropriately negative redox potential (EoP of the re-
dox pair O2/Oc32 =3330 mV), superoxide may be formed from
atmospheric oxygen. Superoxide dismutates at neutral pH in
aqueous media with a rate constant k = 2U105 (L M31 s31),
yielding hydrogen peroxide. Hydrogen peroxide can be mono-
valently reduced by certain electron donors yielding the ex-
tremely reactive hydroxyl radical, OHc. Electron donors may
be semiquinones or reduced transition metal ions such as Fe2
or Cu. The most prominent candidate is Fe2, stemming
from Fe3 reduced by superoxide, thiols or ascorbate (Haber-
Weiss-Fenton chemistry; see below). The OH radical has a
very positive redox potential (close to +2 V) and a life time
in biological media of approximately 1 Ws thus reacting closely
to the site of its generation producing ‘site-speci¢c’ oxidative
damage (see Section 5). The oxygen species OHc is the major
target of the antioxidative power of phenolics since, due to its
thermodynamic and kinetic properties it is not under the con-
trol of speci¢c enzymes (see Section 6.2).
3.3. Peroxynitrite (ONOOH): a strong oxidant similar to OHc
The simple molecule NOc plays a very important role in the
regulation of vascular tone. It activates the enzyme guanylate
cyclase which produces the vasorelaxing cGMP. NO is syn-
thesized from the amino acid arginine catalyzed by the en-
zyme NO synthase (NOS; EC 1.14.13.39). NO synthesis seems
to proceed in a two step reaction: the ¢rst reaction converts
arginine into NG-hydroxy-L-arginine and is catalyzed by NOS.
The second step is apparently independent of NOS and seems
to be driven by superoxide generated by NADPH oxidases or
by XOD.
Peroxynitrite ONOO3 is formed from nitrogen monoxide
and superoxide in an extremely fast reaction (k = 6.7U109 L
M31 s31) indicating that ONOOH formation is only di¡usion
limited. ONOOH, which is mainly produced under pathophy-
siological conditions (rapid superoxide formation by XOD or
activated neutrophils together with NOS activation) inhibits
NOS where bovine serum albumin, glutathione or tyrosine act
as protectants. ONOOH initiates lipid peroxidation, inhibits
mitochondrial electron transport, inactivates glyceraldehyde
3-phosphate dehydrogenase as well as Na/K-ATPases and
membrane sodium channels.
Experiments with model reactions and inhibitors could
demonstrate that only in the presence of both radicals, NOc
and Oc32 and through their interaction, damage of endothelial
cells occurred. Several authors used di¡erent NO generators
such as S-nitroso-N-acetyl-DL-penicillamine (SNAP), sodium
nitroprusside or 3-morpholino-sydnonimine (SIN-1), where
SIN-1 produces simultaneously both NOc and Oc32 [7].
3.4. Hypohalous acids
Catalyzed by myeloperoxidases (EC 1.11.1.7), halides such
as Cl3 or Br3 are converted into hypohalous acids (HOCl;
HOBr) which are strongly oxidizing or halogenating agents,
produced by activated leukocytes and secreted into the phago-
some or tissues adjacent to these activated blood cells thus
contributing to the degradation of ingested particles or to
in£ammations and tissue damage.
All the above mentioned ROS may interact thus producing
an almost undi¡erentiable set of superimposed oxidants.
Methods suitable for the di¡erentiation of various ROS
such as ONOOH, HOCl and Fenton oxidants have been re-
cently reported [8,9].
The most important ROS are summarized in Table 1.
4. Transition metal-catalyzed oxidations and hydroxylations
At the end of the last century Fenton [10] described the
ability of hydrogen peroxide to oxidize aromatic compounds
in the presence of iron salts (Fenton’s reagent). Later on Haber
and Weiss [11] concluded that the reactivity of Fenton’s re-
agent was due to the formation of OH radicals according to
the following reaction sequence:
I Fe2 H2O2!Fe3 OH3 OHc
II OHc H2O2!H2OH Oc32
III Oc32 H2O2!O2 OH3 OHc
IV Fe3 H2O2!Fe2  2H Oc32
V Fe3 Oc32 !Fe2 O2
Details of the thermodynamics of the Fenton-driven Haber-
Weiss and related reactions have been described in [12].
The Udenfriend group reported in 1954 (see reference in
[13]) that at neutral pH and room temperature, aromatic com-
pounds are hydroxylated by molecular oxygen in the presence
of Fe2, ascorbic acid and EDTA. This mixture, designated
the ‘Udenfriend system’, was later described as also hydrox-
ylating saturated hydrocarbons yielding alcohols and forming
epoxides from ole¢ns [13]. The oxidizing species of this reac-
tion mixture is supposed to be a complex of oxygen, Fe2 and
ascorbic acid transferring triplet oxygen to the substrate (S).
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Table 1
The most important reactive oxygen species
Free radicals Atmospheric oxygen, cO2 c (diradical)
Superoxide radical anion, Oc32
Hydroperoxyl radical, HOc2
OH radical, OHc
Alkyl and alkoxyl radicals, Rc, ROc
Peroxyl radicals, ROOc
Nitrogen monoxide or dioxide, NOc and NOc2
Non-radical
compounds
Hydrogen peroxide, H2O2
Organic peroxides, ROOH
Hypohalous acids or their salts, such as HOCl, OCl3
and organic chloramines such as taurine chloramine
Peroxynitrite, ONOOH
Singlet oxygen, 1O2
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The general reaction mechanism may be formulated as shown
in Fig. 1 (upper part).
In analogy, ascorbate can be replaced by tetrahydropteri-
dines or by catechol (references in [13]) which hydroxylates
aromatics in the presence of Fe3 (‘Hamilton system’).
It has been shown with several model systems that substrate
oxidations and hydroxylations can be observed in the absence
of a reducing agent if the reduced TMI is present at high
enough concentrations. In this respect iron can be replaced
by Cu(I), V(II), Ti(III) or Sn(II). In this type of reaction two
metal ions are electronically connected by a bridging group
allowing overlapping of molecular orbitals of both TMIs
(references in [13]) (Fig. 1, lower part).
5. OH radicals, ferryl-perferryl (cupryl-percupryl) complexes,
‘active site’ complexes or crypto-OH? The long-lasting
dispute on the nature of the strongly oxidizing TMI-ROS
species
The interactions between TMI and oxygen or ROS are ex-
tremely complex and not yet understood in all details : oxygen
transport and oxygen activation producing ROS as well as
ROS detoxi¢cation [2] and complex, biologically important
metal-metal interactions [14] have to be distinguished. In
this context only the production of extremely strong oxidants
of the OH radical type will be addressed. There is no doubt
that the free OH radical exists in the atmosphere [15] and is
produced in radiation chemistry [16]. In biological systems,
however, the ongoing dispute in the past was and is the ques-
tion if, in the presence of TMI, superoxide and hydrogen
peroxide, free OHc is the species which brings about the dam-
age or whether transient reaction products between TMI and
superoxide or hydrogen peroxide might be reactive enough to
rapidly (ks 108) interact with molecules in the near neighbor-
hood (‘active site chemistry’). Such transient products might
be designated ‘cage molecules’ as postulated for peroxynitrite
[17], as electron donor-hydrogen peroxide complex [18] or
‘crypto-OH’ [19]. Whatever might be the most appropriate
name for such a species derived from superoxide or hydrogen
peroxide in the presence of TMI, the ‘active site chemistry’
might be drawn as outlined below [20].
VI CuII ÿ BiolOc32 !CuI ÿ BiolO2
VII CuI ÿ BiolH2O2!OH3  CuII ÿ BiolÿOHcgf
where {Cu(II)-Biol^OHc} stands for ‘active site’ copper ion
creating an OH-type radical near the target molecule. This
species might also be designated ‘crypto-OHc’ formed in the
solvent cage as stated above.
The corresponding activities of di¡erent TMI-ROS com-
plexes are not identical, however. Kocha et al. [21] compared
the e¡ects of copper ions with the e¡ects of iron ions in the
presence of hydrogen peroxide and EDTA as to oxidative
albumin degradation. This was taken as the basis for the
assumption that copper binds site-speci¢cally according to
the Czapski scheme ([20]; reactions VI and VII) while Fe-
EDTA generates an OH-type oxidant in solution.
6. TMI mobilization from storage proteins and regulation of
homeostasis
6.1. TMI mobilization
Under reductive conditions (ascorbate; superoxide; quinoid
redox cyclers; cf. [22]) iron is released from storage or trans-
port proteins (such as transferrins and ferritin) or, in the case
of copper, by peroxynitrite from ceruloplasmin [23]. Most of
the transferrin-bound iron is used for hemoglobin (Hb) syn-
thesis and released again from Hb after senescence of eryth-
rocytes and internalization by macrophages. Released iron is
then rebound by transferrin thus completing the iron cycle.
During this cycle iron concentrations exceeding the require-
ment for hemoglobin synthesis enter a ‘‘poorly characterized
labile intercellular pool’’ [24].
Iron release from Hb is observed after allyl alcohol intox-
ication where desferrioxamine (Desferal, DF) inhibits hemol-
ysis and lipid peroxidation [25]. Reperfusion after open heart
surgery results in hemolysis yielding free heme and iron ac-
companied by formation of OH radicals presumably via the
xanthine oxidase reaction [26].
Malaria parasites may release iron from Hb via acidi¢ca-
tion of their food vacuoles initiating Fe-redox cycling which is
enhanced by vitamin C [27]. In a rabbit lung reperfusion
model damaging Fe ions seem to stem from cytochrome
P450 [28].
Iron release from ferritin driven by superoxide causes lipid
peroxidation [29] where the rate constant of the reaction be-
tween superoxide and iron-ferritin has been determined to be
ca. 2U106 L M31 s31 [30].
6.2. ROS detoxi¢cation and regulation of TMI homeostasis
As already mentioned, detoxi¢cation by enzymic processes
is only possible if the reactivity of the oxygen species in ques-
tion is reasonably low under physiological conditions so that
the enzymic reaction allows at least one k order of magnitude
between the reaction under enzyme catalysis and the non-cat-
alyzed spontaneous reaction between the oxygen species and
any reaction partner in its ‘molecular’ neighborhood. There-
fore, the reactions of OHc, 1O2, ROc, ROOc and HOOc are not
under enzymic control since their reaction constants with po-
tential partners in their typical ‘environments’ are too fast
(generally kE108) for enzyme catalysis. Thus, the reactions
of biomolecules with these oxygen species have to be
‘amended’ after their reaction, i.e. damage. In order not to
‘£ood’ these repair process antioxidative small molecules serve
as scavengers and quenchers of activated states [1,3,5,31].
Enzyme-catalyzed detoxi¢cations mainly concern superox-
ide, peroxides and epoxides (produced by cytochrome P450
activities) as more or less ‘stable’ reduced oxygen species.
In most aerobic cells catalase, superoxide dismutases
FEBS 21400 18-1-99
Fig. 1. Possible reaction mechanisms of oxidations by the ascorbate-
iron (Udenfriend) system and of substrate oxidations by Cu(I).
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(SOD), ascorbate peroxidase, mono- or dehydro-ascorbate re-
ductases, glutathione peroxidase, glutathione reductase, and
di¡erent peroxidases either individually or cooperatively re-
move stable ROS [3,5].
Homeostasis of TMI in aerobic cells is modulated by reg-
ulatory proteins controlling uptake, transport, storage and
release. Metallothioneins in animals [32] and phytochelatins
in plants [33] are sulfhydryl-rich proteins involved in metal
binding and thus detoxi¢cation by sequestering free heavy
metal ions and also TMI. Iron metabolism in animals is regu-
lated by iron regulatory proteins (IRPs). These proteins bind
to iron-responsive elements of mRNA for ferritin and to the
transferrin receptor. As regulators of IRP activities, available
cellular iron [34], cellular redox status [35], ROS [36,37] and
NOS activity [38] have been described. IRP-1, which contains
a [4Fe-4S] cluster [39] and acts as a cytoplasmic aconitase, is
rapidly inactivated by iron-releasing redox cyclers such as the
doxorubicin metabolite. This reaction might partially explain
the cardiotoxicity of these anticancer compounds [40]. Belin-
kova and coworkers recently reported that inactivated aconi-
tase is identical with the active oxaloacetate keto-enol tauto-
merase [41].
TMI in the bad sense may be converted into good: DF
converts ‘toxic’ Fe into the redox-inactive Fe-DF, Mn into
a SOD mimetic; similarly penicillamine converts free Cu
into SOD-active Cu-penicillamine [42].
7. Pathological processes
TMI can be either inhaled as ¢bers, dust, soot or aerosols
and thus exert toxic reactions or mobilized by microorganisms
after infection or ingested as toxins produced by them. For all
three cases a few examples will be given.
7.1. Intoxications and infections
7.1.1. Inhaled particles. Airborne particulate matter such
as soot particles from diesel engines, coal or oil burners, or
¢bers such as asbestos may cause in£ammatory responses in
the respiration tract via activation of alveolar macrophages.
Besides geometrically determined interactions these particles
contain substantial amounts of TMI and thus act catalytically
as ‘immobilized’ converters interacting with di¡erent ROS
[43,44]. These particles in many cases are emitted together
with sulfur dioxide which exerts a cooperative e¡ect on the
destructive potential together with a change in the basic re-
action mechanism. This holds for both crocidolite asbestos
¢bers and diesel soot particles [45,46]. Stimulation of bio-
chemical model reactions (NADH/diaphorase system: the en-
zyme generates superoxide at the expense of NADH, so this
model simulates the respiratory burst of activated leukocytes),
indicative of oxidative destructions, their stimulation by
EDTA and their inhibition by DF and SOD, is taken as proof
for the involvement of both iron and superoxide in these re-
actions (Fig. 2) [46]. According to a recent report Fe seems to
cooperate with NO in asbestos-catalyzed mutagenicity and
carcinogenicity [47].
Hard metal lung diseases are caused by exposure to toxic
metal mixtures consisting of Co metal and tungsten carbides
(TC). Toxicity is only exerted in the presence of both compo-
nents, Co and TC [48]. The mechanism by which toxicity is
mediated is rather complex, involving metal-metal surface in-
teractions in the particle-biological medium interface [49]. In a
¢rst reaction metallic Co is ionized accompanied by TC-cata-
lyzed oxygen reduction:
VIII Coÿ TC!Co2 ÿ TC 2e3
IX 2O2  2e3ÿTCÿOc32 !2Oc32
7.1.2. Intoxications. Ingestions of a toxic load of TMI
with food or drinks and thus development of disease symp-
toms are not a matter of discussion in this short review. There
is yet another possibility of evoking TMI toxicity, namely the
uptake of poisonous redox catalysts (RC) either willingly
(chemotherapy; antimalarials) or unwillingly (paraquat; orel-
lanine). In these cases TMI may be mobilized by the above
mentioned redox mechanisms. In this context the herbicide
paraquat and the fungal poison orellanine have to be men-
tioned.
Paraquat, like other low potential bipyridyls, reduces oxy-
gen monovalently after its reduction by diverse oxidoreduc-
tases (diaphorases). As shown for paraquat (1,1P-dimethyl-
4,4P-bipyridylium dichloride) [19] and very recently also for
lucigenin (bis-N-methylacridinium) [50], formation of OH-
type oxidants under aerobic conditions is strongly enhanced
by the addition of Fe salts and lipid peroxidation by bipyr-
idyls is directly dependent on their potential to reduce Fe3
[51].
Iron strongly enhances paraquat toxicity in living individu-
als such as Escherichia coli [52], animals such as £ies (Droso-
phila melanogaster [53]) or mice, where toxicity was abolished
by DF [54]. In vitamin E-de¢cient rats, however, DF, in con-
trast to the lipid-soluble iron chelator CP51 (a hydroxypyri-
din-4-one derivative), had no signi¢cant e¡ect on mortality
[55]. One mechanism of paraquat toxicity in copper-tolerant
cell lines (hepatocytes) may be copper-dependent glutathione
depletion [56], a reaction which has been shown to proceed via
a peroxide- or a superoxide-dependent pathway starting from
a Cu2(GS3)2 complex [57].
Orellanine ([2,2P-bipyridine]-3,3P,4,4P-tetrol-1,1P-dioxide) is a
toxin produced by the fungus Cortinarius orellanus causing
lethal nephrotoxicity. In vitro it forms a stable ferric complex
which is easily reducible. At neutral pH it undergoes one
electron transition producing the o-semiquinone anion radical.
In the presence of Fe2 orellanine causes rapid oxygen con-
sumption by facilitating Fe2 autoxidation [58].
Bleomycin (Bl), like doxorubicin and numerous other anti-
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Fig. 2. The oxidative capacity of crocidolite and diesel soot in the
NADH/diaphorase system.
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cancer drugs, exerts both desired and undesired health e¡ects
on the basis of iron binding (Bl-Fe) and thus ‘site-speci¢c’
oxygen activation. After intercalation with DNA preferen-
tially in tumors, Bl-Fe causes strand breaks and degradation.
In contrast to other oxidative destructions this process is ap-
parently stimulated by glutathione [59], glutathionyl-hydro-
quinone (a toxic benzene metabolite [60]) and antioxidants
such as ferulic acid, epicatechin and þ catechins [61].
Inhibitors of Bl-Fe- or doxorubicin-catalyzed damage in-
clude compounds such as baicalein (5,6,7-trihydroxy-2-phen-
yl-4H-1-benzopyran-4-one [62]) and the bispiperazinedione,
dextrazoxane (ICRF-187), which form inert complexes with
iron in several model systems and are thus used as organ-
protective drugs during chemotherapy [63].
Several phenolics and £avonoids known as potent antiox-
idants exhibit equivocal responses, however: mono- and tri-
hydroxyethylrutosides inhibited negative inotropic e¡ects of
doxorubicin treatment [64] while BL-Fe-induced DNA dam-
age was augmented by catechins and ferulic acid [61].
7.1.3. Infection. The so-called hospitalism bug Pseudomo-
nas aeruginosa causes severe lung disease by releasing both the
proteinaceous iron chelator pyochelin (PYCH) and the redox-
cycling phenazine derivative, pyocyanin (PYO). Iron seques-
tration and cell toxicity are apparently based on a common
mechanism: superoxide and hydrogen peroxide formation by
PYO, iron release from ferritin by Oc32 , oxidation of Fe
2 by
ceruloplasmin, complexation of Fe3 by PYCH and its reduc-
tion by Oc32 and ¢nally reduction of H2O2 with formation of
OHc driven by PYCH-Fe2. The toxicity of this system has
been shown by following 51Cr release from prelabelled lung
epithelial cells [65].
7.2. General pathoprocesses involving TMI
In the following a few selected examples of the (possible)
involvement of TIM and ROS in certain well known diseases
will be presented.
7.2.1. Atherosclerosis (AS). Low density lipoprotein
(LDL) oxidation in vitro is strongly enhanced by iron or
copper and modulated by pH [66], thiol compounds and anti-
oxidants such as tocopherols, carotenoids and ubiquinol. Oxi-
dized TMI such as Cu2 or Fe3 are readily reduced by mac-
rophages thus facilitating monovalent lipid hydroperoxide
(LOOH) decomposition and chain peroxidation [67]. The Bru-
neck study [68] provides strong epidemiological evidence for a
role of iron in AS events since ‘‘ferritin and LDL-cholesterol
showed a synergistic association with cardiovascular disease
and death’’. It has also been shown that electrophoretic
mobility of LDL (as a marker of its oxidation) in women
correlates with increased ferritin [69]. These reports are in
contrast, however, with a report that iron overload in rabbits
decreases AS rather than increasing it [70]. Therefore a role of
TMI in AS is indicated but the mechanisms are anything but
clear.
Much attention has recently been given to elevated homo-
cysteine and TMI levels [71].
7.2.2. Skin in£ammation and sunburn. In£ammatory skin
diseases have been discussed in context with ROS from in¢l-
trating polymorphonuclear leukocyts (PMNL), TMI and UV
radiation [72]. In the case of sunburn it has been shown that
chronic UV exposure increases free iron in the skin [6] and
that the iron chelator 2-furildioxime and sunscreen provide
synergistic protection [73].
7.2.3. Neurological disorders. ROS are involved in the de-
velopment of neurological disorders such as Parkinsonism,
Alzheimer’s disease (AD), amyotrophic lateral sclerosis, de-
mentia and depressive situations. In addition to Fe and Cu,
aluminum and manganese seem to play a crucial role in
pathogenesis [74]. In AD, similar to atherosclerosis (AS, see
above), Cu reduction seems to be achieved by factors involved
in the development of the corresponding disease: in the case
of AS macrophages [67] and in AD the amyloid precursor
protein [75]. As indicated in Fig. 1 TMIs catalyze one electron
transfer from ortho-diols to oxygen. It is thus quite obvious
that catecholamines are readily oxidized by TMI producing
ROS, O-methylation or addition of melatonin may protect
against ROS production and CA oxidation [76].
Both de¢ciency and excess of Mn experimentally causes
neurotoxicity via ROS generation [77] where subchronic oral
exposure causes changes in monoaminergic systems and in-
creases in uric acid levels [78].
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Fig. 3. Phases of TMI-catalyzed ROS toxicity. For more details see text.
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7.2.4. Joint diseases and rheumatism. Rheumatism, osteo-
arthritis, gouty in£ammations and ¢nally arthrosis are in£am-
matory diseases involving activated PMNL and TMI during
symptom development, counteracted by Zn (as macrophage
immobilizer), Se (furnishing the active center of glutathione
peroxidase) and the chain-breaking antioxidant, vitamin E
[79].
Serum copper is increased in chronic juvenile arthritis [80]
and the copper chelator penicillamine (see Section 5) similar
to Wilson’s disease (see below) is helpful in its treatment [81].
Fe- and XOD- (or PMNL-NADPH oxidase-) catalyzed ox-
idative depolymerization of the joint lubricant hyaluronic acid
[82] during arthritis is seen as a predisposition for arthrosis.
During gouty in£ammation, incomplete and thus redox-ac-
tive complexation of Fe by urate crystals and enhancement of
ROS production have been described as possible causes for
symptom expression [83].
7.2.5. Ischemia-reperfusion. schemia-reperfusion damage
of lung, intestine, heart and other organs is connected with
ROS formation (especially by the xanthine oxidase reaction
and activated PMNL), iron mobilization and thus Fenton/
Haber-Weiss chemistry [84]. Reperfusion injury can be ame-
liorated by iron chelators such as DF, lipophilic siderophores
of Mycobacterium tuberculosis (‘exochelins’ [85] ; in analogy to
the hydrophilic pyochelins of P. aeruginosa, see Section 7.1.3).
Other natural products representing both antioxidant and
TMI chelator activity ameliorating reperfusion injury are pro-
cyanidines from grape (Vitis vinifera) seeds [86].
7.2.6. Other diseases. Elevated copper levels have been
observed in context with ocular in£ammation (uveitis) [87]
and Wilson’s disease as an inborn error in copper metabolism
resulting in enhanced copper levels in the liver probably due
to the de¢ciency in a Cu-transporting ATPase. An animal
model for this disease has recently been presented [88].
A general simpli¢ed scheme characterizing the above mech-
anisms is shown in Fig. 3.
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